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Aim: To assess the impact of bariatric surgery (BS) on incident microvascular complications 
[diabetes-related foot disease (DFD), sight threatening diabetic retinopathy (STDR), chronic 
kidney disease (CKD)] in patients with type 2 diabetes and obesity. 
Methods: A retrospective matched, controlled population-based cohort study of adults with 
type 2 diabetes between 1/1/1990 and 31/1/2018 using IQVIA Medical Research Data 
(IMRD), a database of primary care electronic records. Each patient with type2 diabetes who 
subsequently had BS (surgical) was matched on index date with up to 2 patients with type 2 
diabetes did not have BS (non-surgical) within the same general practice by age, sex, pre-
index body mass index and diabetes duration. 
Results: 1126 surgical and 2219 non-surgical participants were included. In the study 
population, 2261 (68%) were women; Mean (SD) age was 49.87 (9.3) vs 50.12 (9.3) years 
and BMI was 46.76 (7.96) kg/m2 vs 46.14 (7.49) kg/m2 in surgical vs non-surgical group 
respectively. In surgical group, 22.1%, 22.7%, 52.2% and 1.1% patients had gastric band, 
sleeve gastrectomy, gastric bypass & duodenal switch respectively. 
Over median (IQR) follow-up was 3.9 years (1.8-6.4), BS was associated with reduction in 
incident combined microvascular complications (adjusted HR 0.63, 95% CI 0.51 to 0.78, 
p<0.001), DFD (0.61, 0.50 to 0.75, p<0.001), STDR (0.66, 0.44 to 1.00, p<0.001), CKD 
(0.63, 0.51 to 0.78, p<0.001). Analysis based on the type of surgery showed that all types of 
surgery were associated with favourable impact on the incident of composite microvascular 
complications, greatest reduction RYGB. 






The rising levels of obesity and type 2 diabetes are major global health challenges. Vascular 
complications (microvascular and macrovascular) are the major causes of morbidity and 
mortality in patients with type 2 diabetes (1, 2).  
Worldwide, the cost of health expenditure due to diabetes has increased from USD 232 
billion in 2007 to USD 727 billion in 2017 and estimated to rise further to USD 825billion by 
2030. The major portion of direct cost in diabetes management is spent in managing diabetes 
related complications and its consequences (2). The cost of diabetes management had been 
estimated to be 20 times more in patients with four or more diabetes related complications 
compared to patient with diabetes with no complications. (2). In the United Kingdom, 
diabetes accounts for 10% of the National Health Service (NHS) budget and 80% of this 
expense is spent dealing with diabetes-related complications mainly due to prolonged 
hospital stay, cardiovascular disease, kidney disease and neuropathy (3).  
Despite improved clinical management of type 2 diabetes over the last 2 decades including 
new classes of glucose lowering medication (Dipeptidyl peptidase-4 inhibitor, sodium -
glucose cotransporter2 inhibitor, glucagon like peptide-1 agonist) reduction in microvascular 
complications are far less compared to the reductions observed in cardiovascular disease (4). 
Diabetes-related foot disease (DFD) is the leading cause for non-traumatic lower limb 
amputation in the developed world (5); sight threatening diabetic retinopathy (STDR) is a 
leading cause of blindness at younger age (6), and diabetic nephropathy is the leading cause 
of chronic kidney disease (CKD) and end-stage renal disease (7).  
Obesity is an established risk factor for type 2 diabetes, hypertension and hyperlipidaemia 
(8). In addition, obesity is an independent risk factor for CKD (9), peripheral neuropathy (10-
12), cardiovascular disease (13) and mortality (14). A number of studies have shown that 
intentional weight loss is associated with improvements in glycaemic control, blood pressure, 
hyperlipidaemia and other vascular risk factors (15, 16). Amongst the several interventions 
for the treatment of obesity, bariatric surgery (BS) provides the most significant and 
sustainable weight loss and has a favourable impact on glycaemic control and other vascular 
risk factors (17-19). We have recently shown that BS in patients with and without type 2 
diabetes was associated with reduction in incident hypertension, cardiovascular disease and 
all-cause mortality compared to routine care (20). Hence, it would be expected that BS 
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surgery may also reduce the incidence of microvascular complications in patients with type 2 
diabetes.  
Currently, the impact of BS on diabetes-related microvascular complications remains unclear. 
A meta-analysis of 10 studies (3 RCTs and 7 controlled studies) involving 17532 patients 
found an overall reduction in incidences of retinopathy and nephropathy, but not neuropathy, 
in the surgical arm compared to the non-surgical arm; but there was heterogeneity in findings 
and in the definition of microvascular outcomes between the studies(21) . Hence there is lack 
of large, population-based studies examining the impact of BS on individual diabetes-related 
microvascular outcomes. 
Our hypothesis was that BS is associated with a reduction in incidence of microvascular 
complications compared to routine care in people with type 2 diabetes and obesity. 
We therefore conducted a population-based matched controlled cohort study to assess the 
impact of bariatric surgery on incident microvascular complications in patients with type 2 
diabetes. We also examined the findings stratified by individual bariatric procedures. 
Methods 
Study design and data source 
A retrospective matched controlled cohort study utilising IQVIA Medical Research Data 
(IMRD), database was conducted. IMRD is an electronic primary care database that includes 
longitudinal patient records of over 15 million patients, of which 3.7 million are currently 
active (contributing data to the database). The database covers around 6.2% of the UK 
population and has been shown to be representative of the UK demographic structure (22). 
IMRD contains demographic information, clinical diagnoses, procedures, laboratory results, 
medications, lifestyle information and every consultation episode with primary care. IMRD 
(previously referred as THIN database) has previously been used for research related to 
diabetes and vascular outcomes (23-27) and to assess effectiveness of bariatric surgery (20, 
28). 
Study population 
Primary care practices were eligible for inclusion in the study if they had been using the 
Vision electronic records system for at least one year, and had Acceptable Mortality 
Reporting (an indicator of the practice data quality) for at last one year before study entry 
(29). In addition, study participants must have been registered with an eligible practice for at 
least one year before study entry. The above-mentioned criteria were to ensure data extracted 
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was high quality with adequate documentation of concomitant diseases and treatments. The 
surgical cohort were adult patients (18 years and above) with obesity (BMI ≥ 30 kg/m2) who 
had type 2 diabetes and a subsequent record of a primary BS [gastric banding (GB), sleeve 
gastrectomy (SG), Gastric bypass (RYGB), duodenal switch (DS)]. Each patient with type 2 
diabetes who had bariatric surgery (surgical) was matched on index date with up to 2 patients 
with type 2 diabetes who did not have bariatric surgery (non-surgical) within the same 
general practice by age (± 2 years), sex, pre-index body mass index (BMI, ±2 kg/m2) and 
diabetes duration (± 3 years). Patients in the surgical group and their corresponding non-
surgical were excluded from the study if they met any of the following criteria: had a BMI 
<30 kg/m2, age >75 years, gastric balloon or endo-barrier or gastric cancer before bariatric 
surgery or had been coded as type 1 diabetes (Figure 1). 
Follow-up 
Index date for the surgical cohort was the date of bariatric surgery. For the non-surgical 
population, index date was assigned as the corresponding index date of their matched surgical 
patient to mitigate immortal time bias (30). Eligible participants were followed-up from the 
index date until the earliest occurrence of the following end points: a) incidence of the 
outcome of interest; b) death; c) patient left the practice; d) the practice ceased contributing to 
the database; or e) study end date (31/1/2018). 
Outcome measures  
The primary outcome measures were composite microvascular disease, DFD, STDR and 
CKD. Outcomes were defined by a rigorous process of clinical Read code selection (31), 
reviewing them against existing literature and ratifying through an expert panel of specialists 
in the field and primary care professionals. 
DFD was defined as a composite of either foot ulcer, gangrene, deformity or amputation, 
moderate/high foot risk, peripheral vascular disease (PVD) or diabetes-related peripheral 
neuropathy (DPN) according to Read codes in the IMRD database (definition DFD1). 
Moderate foot risk was defined as presence of DPN, deformity or non-critical limb 
ischaemia. High foot risk was defined as previous ulcer, amputation, more than 2 of the 3 
parameters of DPN, deformity or PVD (32, 33). We considered alternative definitions for 
DFD in the analysis. DFD2 was defined as any of the components of DFD1, not including 
PVD/ DPN codes. DFD3 was defined as any of the components of DFD2 without including 
moderate/high foot risk codes. In addition, we explored the risk of incident DPN and PVD 
separately, as secondary outcomes. 
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STDR was defined as either pre-proliferative retinopathy (R2), proliferative retinopathy (R3) 
or maculopathy (M1); retinopathy treatment (photocoagulation/vitreous injection); or vision 
loss (24). In a sensitivity analysis, we excluded vision loss from the outcome definition, as 
this may have been caused by pathologies other than diabetes such as macular degeneration 
or cataract. 
CKD was defined as eGFR <60 ml/min/1.73m2 or albuminuria (Albumin creatinine ratio, 
ACR ≥3mg/mmol) (34). In addition, we looked at eGFR <30 ml/min/1.73m2 and macro-
albuminuria (ACR >30 mg/mmol) separately. We used the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation to calculate the eGFR value from the 
creatinine value (35). In sensitivity analysis, we defined two consecutive values of eGFR <60 
ml/min/1.73m2 and two consecutive ACR ≥3mg/mmol as outcomes. In both analyses, 
patients who had the outcome measure of interest before the index date were excluded. 
All outcomes defined above are assessed annually as part of the Quality and Outcomes 
Framework (QOF) scheme in primary care and are therefore likely to be accurate; this regular 
assessment also mitigates surveillance bias (36). 
Statistical analysis 
Baseline characteristics were summarised as mean (±standard deviation, SD) or median 
(interquartile range, IQR) for continuous variables and proportions for categorical variables. 
Covariates in the adjusted/multivariable model were selected based on biological plausibility; 
these included age, sex, high BMI, smoking status, ethnicity, and social deprivation status, 
hypertension status, DM duration, baseline HbA1c and medications including ACE 
inhibitors, anti-lipid drugs and insulin. BMI (in kg/m2) was categorised as <35 kg/m2, 35-40 
kg/m2 and > 40 kg/m2. Smoking were categorised as smoker, non-smoker, and ex-smoker. 
Social deprivation status was represented by Townsend deprivation quintile which is based 
on material deprivation within a population (31). Ethnicity was categorised as Caucasian, 
Afro-Caribbean, south Asian, mixed. A missing category was used for missing data for BMI, 
Townsend quintile, smoking status, and ethnicity. Hypertension status and medications were 
handled as binomial variable and age, DM duration and baseline HbA1c as continuous 
variables.  
We calculated crude and adjusted hazard ratios (adjHR) and 95% confidence intervals (CIs) 
for the occurrence (incident) of each outcome of interest in the surgical versus non-surgical 
groups using a Cox proportional hazards regression model. Participants with the outcome of 
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interest in the surgical or non-surgical group at baseline were excluded from the respective 
analysis. For CKD analysis, we also excluded the patients on renal replacement therapy 
defined as patient with renal transplant or on dialysis at baseline. 
The proportional hazards assumption was checked using the Schoenfeld residuals test. We 
adjusted for biologically plausible confounders as mentioned above. 
Stratifying by type of surgery, we analysed the outcome in participants undergoing gastric 
band, sleeve gastrectomy and gastric bypass and their corresponding non-surgical control 
group. We did not perform analysis in the duodenal switch subgroup due to small numbers. 
We know that beneficial effects of BS on weight loss and glycaemic control lessen overtime, 
so we reported the latest weight and HbA1c to avoid inflation of results in favour of surgery. 
Post-surgical weight was defined as latest weight available for surgical or non-surgical group 
after the index date and before the exit date. Percentage weight loss (%WL) was calculated as 
    
 
100. For the non-surgical group who 
had no surgery, weight change was calculated using latest weight after the index date and 
baseline weight. Independent sample t-test was used to compare the %WL in surgical and 
non-surgical groups. HbA1c was standardized as a percentage (Diabetes Control and 
Complications Trial, DCCT unit). We calculated the change in HbA1c (latest HbA1c 
available after the index date minus baseline HbA1c) and used independent sample t-test to 
compare percentage difference between surgical and non-surgical groups. 
We used Nelson-Aalen plots (non-parametric estimator) to present the cumulative hazard 
function for each outcome over 10-year periods. A two-tailed p-value <0.05 was considered 
statistically significant. All analyses were conducted using Stata version 15. 
Results 
Baseline characteristics 
We included 1126 surgical and 2219 non-surgical participants. Baseline characteristics are 
summarised in Table 1. Mean (SD) age was 50 (9.3) years; and 2261 (67.59%) participants 
were women. Mean (SD) BMI was 46.76 (7.96) kg/m2 vs 46.14 (7.49) kg/m2 and mean (SD) 
HbA1c was 7.78% (1.82) vs 7.82% (1.69) for surgical vs non-surgical participants, 
respectively. Median (IQR) DM duration was 4.72 (2.17-8.93) vs 4.63 (1.91-8.19) years in 
surgical vs non-surgical participants. Most of the study population (88.9% of the surgical and 
82.1% of the non-surgical) were not recorded as active smokers. Insulin was prescribed for 
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270 (23.98%) vs 315 (14.20%) of the surgical vs non-surgical participants, respectively. The 
prevalence of microvascular complications at baseline was similar in the surgical and non-
surgical groups. 
Out of 1126 participants in surgical group, 249 (22.1%), 255 (22.7%), 610 (52.2%) and 12 
(1.1%) patients had GB, SG, RYGB and DS, respectively. 
Weight change 
Data on weight before and after index date was available for 1067 (94.8%) surgical and 1943 
(87.6%) non-surgical participants. Over the median (IQR) follow-up of 2.8years (1.2- 4.9 
years) in surgical vs 3.4 years (1.5- 5.6 years) in non- surgical group, surgical group achieved 
a greater %WL (mean, SD) of 21.6% (13%) compared to 4.6% (9.7%) in the non-surgical 
group. 
Participants who underwent surgery lost more weight compared to their matched non-surgical 
for all surgical procedures: GB 14.6% (13.9%) vs 4.6% (10.3%), p<0.001; SG 20.6% 
(11.5%) vs 4.2% (10.1%), p<0.001; RYGB 25.0% (12.0%) vs 4.8% (9.1%), p<0.001; and DS 
21.2% (10.8%) vs 1.7% (9.3%), p<0.001. 
Glycaemic control 
HbA1c values before and after index date were available for 1043 (93%) surgical and 1958 
(88%) non-surgical participants. Over the median (IQR) follow-up period of 2.6 (1- 4.9 
years) in surgical group vs 3.1 years (1.2- 5.5 years) in non- surgical group, participants in the 
surgical group achieved a mean reduction in HbA1c of 1.3% (95% CI 1.2-1.5) [14.2 
mmol/mol, (13.1- 16.4)] while in non-surgical HbA1c increased by 0.2% (95% CI 0.1-0.3) 
[2.2 mmol/mol, (1.1- 3.3)]. The mean HbA1c reduction difference between surgical and non-
surgical cohorts was 1.5% (95% CI 1.4-1.7) [16.4 mmol/mol (15.3- 18.5)]. Participants 
receiving any of the surgical procedures achieved greater HbA1c reductions compared to 
non-surgical with a mean reduction difference of 1% (95% CI 0.7-1.3) [10.9 mmol/mol (7.6- 
14.2] in GB, 1.4% (1.1-1.7) [15.3 mmol/mol (12.0- 18.5)] in SG, 1.8% (1.6-2.0) [19.6 
mmol/mol (17.4- 21.8)] in RYGB and 2.4% (0.8-4.0) [26.2 mmol/mol (8.7- 43.6)] in DS. 
Composite microvascular disease 
BS was associated with 47% reduction in the hazard of developing composite microvascular 
complications vs. non-surgical (adjHR 0.53; 95% CI 0.43 to 0.66) over the median (IQR) 
follow up period of 2.2 year (1-4.4 year).  
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Analysis based on the type of surgery showed that all types of surgery were associated with 
favourable impact on the incident of composite microvascular complications. The adjHRs 
and follow up duration in each surgical procedure can be found in table 2. 
Diabetes-related foot disease, peripheral neuropathy, and peripheral vascular disease 
BS was associated with reduction in the hazards of incidence DFD1 by 39% (p<0.001). 
Analysis based on the type of surgery showed that all types of surgery were associated with 
favourable impact on the incident of DFD1, but this reached statistical significance only in 
the RYGB and GB group, but not in SG group.(Table 2) 
BS was associated with reduction in incidence DFD2 by 37% (p<0.001) and DPN by 28% 
(p=0.037). There was non-significant reduction in hazards of DFD3 and PVD in surgical 
group vs non-surgical group in adjusted analysis (Table 3) 
Sight threatening diabetic retinopathy 
Over the median (IQR) follow-up of 3.5 years (1.6-5.7), BS was associated with 34% 
reduction in incidence of STDR (p=0.048). In a sensitivity analysis excluding low 
vision/blindness in the outcome definition, we found a 42% reduction in incidence of STDR 
in the surgical group compared to the non-surgical group, (p=0.021) (Table 2). 
Stratifying by the type of BS showed that there was a statistically significant decrease in 
incident STDR in the GB cohort vs their non-surgical, but no association was observed in SG 
or RYGB group (Table 2). 
CKD 
Over the median (IQR) follow-up of 2.7 years (1.1-4.9), there was a 37 % reduction in 
incident CKD in the surgical group compared to the non-surgical group, (p<0.001) (Table 2). 
Examining the data based on the type of BS showed that all types of surgery were associated 
with favourable impact on incident CKD, but this was statistically significant in RYGB and 
SG, but not in GB (Table 2). 
No significant association was observed between BS and incident eGFR <60 ml/min/1.73 m2 
or <30 ml/min /1.73 m2 (Table 4). 
There was a 40% reduction in incident albuminuria in the surgical group compared to the 
non-surgical group (p<0.001), and a 64% reduction in macroalbuminuria (p=0.009) (Table 4). 
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In a sensitivity analysis, the observed association of BS with reduction in incidence 
microalbuminuria defined with two consecutive measurements ACR ≥3mg/mmol persisted 
with adjHR of 0.52 (95% CI 0.37- 0.72). But no association of BS and incidence eGFR <60 
ml/min/1.73 m2(2 consecutive results) was found. 
Nelson-Aalen cumulative hazard estimates for study outcomes 
The cumulative hazard estimates for the study outcomes over a 10-year period can be found 
in Figure 2. The figure illustrates the association between BS and the reduction in incident 
composite microvascular complications, DFD1, STDR and CKD. The impact of BS on 
incident DFD1 and CKD was apparent within the first 2-3 years post-surgery while the 
impact on STDR took longer to become apparent (5-6 years). 
Discussion 
Our study provides real-world population-based data showing that BS was associated with 
significant reduction in incident composite microvascular complications, DFD, STDR, CKD 
and DPN in patients with type 2 diabetes compared to routine care, after accounting for many 
potential confounders. The association between BS and reduction in incident STDR took 
longer to become apparent compared to the other microvascular complications (Figure 2). In 
addition, bariatric surgery was associated with greater reductions in weight and HbA1c 
compared to routine care during the follow-up, with the greatest reductions observed in the 
gastric bypass and duodenal switch groups. 
Our results are similar to other published findings but add novel aspects. Our group 
previously showed in a single centre matched controlled studies that over 3 years BS was 
associated with less estimated glomerular filtration (eGFR) decline (37) and incident 
maculopathy (38) compared to routine care; but these studies were of a small sample size, 
single centre, with limited number of patients. 
Sheng et al also showed that BS was associated with lower risk of incident composite 
microvascular complications in a systematic review, but unlike our study there were no 
results based on individual microvascular complications (39). 
The Swedish Obese Subject (SOS) study, a prospective matched controlled intervention 
study, showed a reduction in the incidence rate of composite microvascular complications in 
patients who had undergone BS (n=343) compared to controls (n=260) (18). However, there 
were limitations in that the majority surgical procedure performed was vertical gastroplasty, 
mean (±SD) diabetes duration in surgical group was short (mean 2.9 ±4.7) years), and there 
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was no assessment of individual microvascular outcomes. In addition, the SOS study started 
before many of the current type 2 diabetes interventions were established (such as the use of 
statins and ACEi/ARB). 
Another study from the United States (US), with a similar design to our study, based on four 
integrated health systems, found that BS was associated with reduction in incident 
retinopathy, nephropathy and neuropathy (40). This study did not examine the impact of BS 
on STDR and the impact on nephropathy was measured only using eGFR and not 
albuminuria.  
After BS, patients show a decrease in fat mass, as well as a loss of lean mass, including 
muscle mass (41, 42). Therefore, it is difficult to differentiate if change in creatinine level and 
creatinine-based eGFR is indicative of true improvement in renal function. However, in our 
study the association between surgery and reduction in incident CKD was mainly driven by 
reduction in albuminuria which is not affected by loss of muscle mass. 
In another study of similar design from Denmark, RYGB was associated with reduction in 
the incidence of microvascular complications (CKD, retinopathy, and neuropathy) similar to 
what we observed in our study (HR 0.53 [95% CI 0.38, 0.73) (43). But in this study, they did 
not report the outcomes of individual microvascular complications and our study adjusted for 
more variables in the Cox regression analysis (such as Townsend social deprivation index). 
The Longitudinal Assessment of Bariatric Surgery (LABS) Study examined the impact of 
RYGB and GB over a follow up period of up to seven years and found beneficial effect on 
weight loss, diabetes and hypertension status (44). While this was a study conducted in 
general population with obesity, our study was specifically focused on people with type 2 
diabetes and reported on comprehensive outcomes of multiple vascular complications. 
LABS-Teen specifically reported the impact of BS on CKD in adolescents with type 2 
diabetes with a sample size of 30. No other microvascular complications were analysed. (45). 
Our study was specific in adults, included multiple bariatric procedures, had a larger sample 
size, and reported on DFD and STDR. 
We have recently shown using the IMRD database that BS was associated with reduction in 
incident CVD, hypertension, and mortality in patients with and without diabetes (20). Taken 
together with the findings of this study, this suggests that BS can play an important role in 
reducing the burden of type 2 diabetes by reducing the incidence of hypertension, CVD, 
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microvascular disease and mortality as well as significant improvements in weight and 
glycaemic control. These benefits were observed despite that more patients in surgical group 
had insulin treatment at baseline. Furthermore, in addition to reducing the personal burden of 
type 2 diabetes, the observed potential benefits are likely to have significant savings in health 
care costs considering the high cost of diabetes-related macro- and micro-vascular 
complications (3) . Despite these potential benefits in people with type 2 diabetes, access to 
BS is limited in most western health care systems; improving access to BS in patients with 
type 2 diabetes might therefore have positive implications for diabetes care (46). 
There are several plausible mechanisms for the observed beneficial effects of BS on incident 
microvascular complications. It is likely that BS exerts its beneficial effects by improving the 
established risk factors for microvascular complications including weight, HbA1c, blood 
pressure, lipids, and CVD (19, 47, 48). In addition, recent data suggest that BS can result in 
sodium glucose co-transporter 2 (SGLT2) inhibition (49) and several studies previously 
showed that BS is associated with increased incretin and GLP-1 responses (50). These could 
contribute to the improved vascular outcomes after BS considering the latest cardiovascular 
outcomes trials in type 2 diabetes showing that GLP-1 receptor agonists and SGLT2 
inhibitors can reduce CVD and CKD (51-53). 
We managed to conduct subgroup analysis by type of procedure which added novelty to our 
study. We showed that all types of surgery included in this study were associated with 
reduction in the incidence of composite microvascular complications vs. the non-surgical 
arm. However, there was some variation in the relationship between the type of surgery and 
individual microvascular outcomes. GB had a favourable impact on DFD and STDR but not 
CKD; SG had a favourable impact on CKD only; and RYGB had a favourable impact on 
CKD and DFD but not STDR. These observations are not fully understood as yet and 
requires further evaluation. 
We could not find any studies comparing the impact of different bariatric procedures on 
microvascular diseases as we did in our study. Based on the systematic review by Billeter et 
al (published in 2018) (21), only 3 studies included all types of surgery in same study (18, 38, 
54). However, none of these papers reported the outcomes based on type of surgery and only 
Johnson et al papers reported on individual microvascular complications again no subgroup 
analysis by types of surgery was reported  
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Limitations and strengths:  
The main limitation of our study is its observational nature, and hence causation cannot be 
proven. However, we used matching and extensive adjustments to account for confounding. 
Participants with the outcome of interest at baseline were excluded from the analysis due to 
methodological considerations. Therefore, any effect of BS in patients who already have 
microvascular complications requires future research. C-peptide data was not available in our 
study dataset as it is not yet a routine care test in United Kingdom; however, we included the 
information on diabetes duration and baseline insulin user and adjusted our outcomes for 
these variable. We had a short follow up period duration. 
Our study has several strengths: we used a validated primary care data source (the IMRD 
database) and used previously by our team (23-27) and other researchers to explore similar 
outcomes (55, 56). Using IMRD allowed us to include a large sample size, matched with non-
surgical, and adjust for several covariates improving the generalisability of our findings. 
Furthermore, the outcomes of our study were measured as part of the Quality Outcome 
Framework (QOF) on an annual basis ensuring consistency in definitions and mitigating 
against detection bias. 
Conclusion 
BS was associated with a reduction in microvascular complications, including DFD, STDR, 
CKD and DPN, in patients with type 2 diabetes and obesity. Improving access to BS could 
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  <41  171 (15.19)  329 (14.83) 
  41‐60  803 (71.31)  1568 (70.66) 
  61‐max  152 (13.50)  322 (14.51) 
  Mean (SD)  49.87 (9.3)  50.12 (9.3) 
Sex, n (%) 
  Male  366 (32.50)  718 (32.36) 
  Female  760 (67.50)  1501 (67.64) 
BMI Categories 
  <35  57 (5.06)  121 (5.46) 
  35‐ 39.9  165 (14.65)  344 (15.50) 
  >=40  901 (80.02)  1748 (78.77) 
  Missing  3 (0.27)  6 (0.27) 
  Mean (SD)  46.76 (7.96)  46.14 (7.49) 
Smoker categories, n (%) 
  Non‐Smoker  563 (50.00)  1189 (53.58) 
  Smoker  125 (11.10)  395 (17.80) 
  Ex‐Smoker  438 (38.90)  633 (28.53) 
  Missing  0 (0)  2 (0.09) 
Drinker Categories, n (%) 
  Non‐drinker  315 (27.98)  625 (28.17) 
  Drinker   688 (61.10)  1403 (63.23) 
  Ex‐ Drinker  74 (6.57)  92 (4.15) 
  Missing   49 (4.35)  99 (4.46) 
Ethnicity, n (%)  
  Caucasian   620 (55.06)  1094 (49.30) 
  Black Afro‐Caribbean  25 (2.22)  37 (1.67) 
  South Asian  32 (2.84)  56 (2.52) 
  Mixed Race  7 (0.62)  10 (0.45) 
  Other  2 (0.18)  9 (0.41) 
  Missing   440 (39.08)  1013 (45.65) 
Townsend, n (%) 
  1 (Least deprivation <20%)  185 (16.43)  250 (11.27) 
  2   178 (15.81)  290 (13.07) 
  3   219 (19.45)  463 (20.87) 
  4  234 (20.78)  492 (22.17) 
  5 (Most deprived >80%)  160 (14.21)  414 (18.66) 
  Missing  150 (13.32)  310 (13.97) 
Baseline comorbidities 
  Mental Health Conditions, n (%) 
    Anxiety  310 (27.53)  526 (23.70) 
19 
 
    Depression  616 (54.71)  1001 (45.11) 
  Cardiovascular Diseases, n (%) 
    Hypertension  620 (55.06)  1239 (55.84) 
    Atrial Fibrillation   26 (2.31)  47 (2.12) 
    Heart Failure  16 (1.42)  46 (2.07) 
    Ischemic Heart Disease  74 (6.57)  165 (7.44) 
    Stroke/TIA  30 (2.66)  70 (3.15) 








    DFD1  350 (31.08)  633 (28.53) 
    DFD2  212 (18.83)  371 (16.72) 
    DFD3  61 (5.42)  106 (4.78) 
    DPN  155 (13.77)  291 (13.11) 
    PVD  126 (11.19)  226 (10.18) 
    STDR  57 (5.06)  151 (6.80) 















  Surgical  Non‐ surgical  Surgical  Non‐surgical  Surgical  Non‐surgical  Surgical  Non‐surgical 
Population, n  477  999  776  1586  1069  2068  645  1354 
Outcome events, n 
(%) 
116 (24.3)  420 (42.0)  125 (16.1)  396 (25.0)  34 (3.2)  96 (4.6)  113(17.5)  385(28.4) 
Person‐years  1478.6  2768.3  2681.7  5271.4  4014.3  8205.3  2108.4  4378.2 
Crude IRR  78.45  151.72  46.61  75.12  8.47  11.7  53.6  87.94 
Follow up   2.4 (1‐ 4.4)  2.1 (1‐4.3)  3.0 (1.3‐ 5.2)  2.8 (1.3‐ 5.0)  3.3 (1.5‐ 5.5)  3.6 (1.5‐ 5.9)  2.7 (1.1‐ 4.9)  2.7 (1.1‐ 5.0) 
Crude HR (95% CI), 
p‐ value 
0.52 (0.42‐0.64), <0.001  0.62 (0.51‐ 0.76), <0.001  0.72 (0.49‐1.07), 0.105  0.61 (0.49‐0.75), <0.001 
Adj HR (95% CI), p‐ 
value 
0.53 (0.43‐0.66), <0.001  0.61 (0.50‐ 0.76), <0.001  0.66 (0.44‐1.00), 0.048  0.63 (0.51‐0.78), <0.001 
Gastric banding 
  Surgical  Non‐surgical  Surgical  Non‐surgical  Surgical  Non‐surgical  Surgical  Non‐surgical 
Population, n  133  240  188  366  240  465  165  308 
Outcome events, n 
(%) 
49 (36.8)  127 (52.9)  39 (20.7)  119 (32.5)  12 (5.0)  36 (7.7)  51 (30.9)  121(39.3) 
Person‐years  514.4  845.9  895.3  1521.9  1223.4  2399.5  692.5  1287.2 
Crude IRR  95.25  150.13  43.56  78.19  9.81  15  73.65  94 
Follow up  3.5 (1‐6.2)  2.7 (1.3‐5.6)  4.3 (2‐ 7.2)  3.8 (1.8‐ 6.3)  4.9 (2.3‐ 7.5)  5.2 (2.6‐ 7.5)  4.1 (1.4‐ 6.5)  3.7 (1.8‐ 6.4) 
Crude HR (95% CI), 
p‐ value 
0.64 (0.46‐ 0.89), 0.008  0.55 (0.39‐ 0.80), 0.001  0.65 (0.34‐ 1.25), 0.194  0.77 (0.55‐ 1.06), 0.112 
Adj HR (95% CI), p‐ 
value 
0.65 (0.46‐ 0.91), 0.013  0.53 (0.36‐ 0.78), 0.001  0.49 (0.24‐ 0.99), 0.048  0.77 (0.55‐ 1.09), 0.144 
Sleeve gastrectomy 
  Surgical  Non‐surgical  Surgical  Non‐surgical  Surgical  Non‐surgical  Surgical  Non‐surgical 





21 (20.2)  73 (35.4)  27 (16.4)  76 (22.7)  6 (2.5)  12 (2.6)  17 (11.6)  65 (23) 
Person‐years  299.07  439.21  484.73  926.2  782.32  1521.87  425.9  756.58 
Crude IRR  70.22  166.21  55.7  82.06  7.67  7.89  39.92  85.91 
Follow up  2.3 (1‐ 4.0)  1.6 (0.7‐ 3.6)  2.4 (0.9‐ 4.3)  2.3 (1‐ 4.1)  2.8 (1.3‐ 5)  2.8 (1.2‐ 4.9)  2.2 (1‐ 4.2)  2 (0.9‐ 4.0) 
Crude HR (95% CI), 
p‐ value 
0.45 (0.27‐ 0.73), 0.001  0.69 (0.44‐1.07), 0.098  1 (0.376‐2.69, 0.989  0.47 (0.27‐ 0.80), 0.005 
Adj HR (95% CI), p‐ 
value 
0.49 (0.29‐ 0.83), 0.008  0.70 (0.44‐ 1.11), 0.13  1.41 (0.49‐ 3.99), 0.523  0.52 (0.29‐ 0.91), 0.023 
Gastric bypass 
Population, n  236  542  413  869  577  1123  329  748 
Outcome events, n 
(%) 
44 (18.6)  220 (40.6)  57 (13.8)  201 (23.1)  16 (2.8)  48 (4.3)  44 (13.4)  197(26.3) 
Person‐years  656.1  1446.46  1277.87  2775.225  1978.4  4206.25  979.26  2288.854 
Crude IRR  67.06  152.1  44.61  72.43  8.087  11.41  44.93  86.069 
Follow up  2.2 (1‐ 4.2)  1.9 (0.9‐ 4.1)  2.6 (1.3‐ 4.4)  2.8 (1.3‐ 4.8)  3.0 (1.5‐ 5.0)  3.5 (1.6‐ 5.6)  2.5 (1‐ 4.4)  2.5 (1‐ 4.8) 
Crude HR (95% CI), 
p‐ value 
0.44 (0.32‐ 0.61), <0.001  0.61 (0.46‐ 0.82), 0.001  0.72 (0.41‐1.27), 0.255  0.52 (0.38‐ 0.72), <0.001 
Adj HR (95% CI), p‐ 
value 















  DFD2  DFD3  DPN  PVD 
  Surgical  Non‐surgical  Surgical  Non‐surgical  Surgical  Non‐surgical  Surgical  Non‐surgical 
N  914  1848  1065  2113  971  1928  1000  1993 
Outcome 
events, n (%) 
147 (16.1)  453 (24.5)  29 (2.7)  64 (3.0)  58 (6.0)  157 (8.1)  29 (3.0)  81 (4.1) 
Person‐years  3314.8  6488.0  4028.9  8457.09  3590.71  7308.73  3642.73  7667.25 
Crude IRR  44.35  69.82  7.2  7.57  16.15  21.48  7.96  10.56 
Follow up  3.3 (1.5‐ 5.4)  3.0 (1.4‐ 5.3)  3.3 (1.6‐ 5.5)  3.6 (1.6‐ 6.0)  3.2 (1.5‐ 5.4)  3.4 (1.5‐ 5.7)  3.2 (1.5‐ 5.4)  3.5 (1.6‐ 5.6) 
Crude HR (95% 
CI), p‐value 
0.63 (0.53‐ 0.76), <0.001  0.96 (0.62‐ 1.48), 0.841  0.63 (0.53‐ 0.76), <0.001  0.75 (0.49‐ 1.15), 0.185 
Adj HR (95% CI), 
p‐value 














  Surgical  Non‐surgical  Surgical  Non‐surgical 




67 (6.96)  174 (9.01)  109 (14.79)  372 (24.64) 
Person‐years  3482.7  7405.5  2525.8  5001.2 
Crude IRR  19.24  23.5  43.16  74.38 










8 (0.8)  28 (1.5)  8 (1.1)  48 (3.2) 
Person‐years  3693.9  7826.8  2907.4  6200.2 
Crude IRR  18.14  22.23  2.75  7.74 










Population, n  963  1931  924  1795 
Outcome 
events, n (%) 
67 (7.0)  174 (9.0)  46 (5.0)  168 (9.4) 
Person‐years  3482.7  7405.5  3419.7  6675.1 
Crude IRR  19.24  23.50  13.45  25.17 
Follow up  3.2 (1.5‐ 5.3)  3.5 (1.4‐ 5.6)  3.3 (1.5‐ 5.4)  3.3 (1.4‐ 5.6) 
Crude HR (95% 
CI), p‐value 
0.83 (0.62‐ 1.09), 0.181  0.53 (0.39‐ 0.74), <0.001 
Adj HR (95% CI), 
p‐value 
0.83 (0.62‐ 1.11), 0.21  0.52 (0.37‐ 0.72), <0.001 
IRR= Incidence Rate/1000 person‐years 
Crude HR=Unadjusted Hazard Rate ratio 
Adj HR= Adjusted Hazard Rate ratio; Adjusted for age, sex, smoking status, baseline BMI category, 
ethnicity, Townsend quantile, hypertension, diabetes duration and baseline HbA1c and medications 
including ACE inhibitors, anti‐lipid drugs and insulin. 
 
